Veridex’s Acquisition of Immunicon’s Assets

Cravath represented Veridex, LLC, a Johnson & Johnson company, in its acquisition of substantially all the assets of Immunicon Corporation and its subsidiaries. Immunicon, a public company based in Huntingdon Valley, Pennsylvania, with additional operations in the Netherlands, develops and commercializes proprietary cell- and molecular-based human diagnostic and life science research products. In connection with the acquisition, Immunicon Corporation and its subsidiaries filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware on June 11, 2008. The acquisition will be conducted under the provisions of Section 363 of the U.S. Bankruptcy Code and will be subject to Bankruptcy Court approval and an auction process to be approved by the Bankruptcy Court.

The lawyers involved in this matter are associates Leigh M. Harlan and Raneshia L. Smith on corporate matters; associate Robert H. Trust on corporate restructuring matters; partner Lauren Angelilli and associate Vinay Shandal on tax matters; and partner Eric W. Hilfers and associate Daniel A. Birnhak on executive compensation and benefits matters. The deal was announced on June 11, 2008.